The effect of high dose intravenous immunoglobulin injection on barren women

Investigating the effect of high dose intravenous immunoglobulin injection on pregnancy outcome and immunological factors in infertile women candidates for IVF and repeated implantation failure.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240809062700N1

Enrollment

Registered

2024-09-17

Start date

2024-10-22

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility. Female infertility, unspecified

Interventions

Intervention 1: Intervention group: IVIG protocol: they receive the first dose of IVIG on day 8 to 10 of the stimulating cycle (25 grams). If pregnancy is confirmed by HCG level and ultrasound, IVIG i

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Infertile women diagnosed with Repeated implantation failure (RIF) (at least two previous In vitro Fertilization (IVF) failures) 20 to 40 years old Patients with good quality embryos

Exclusion criteria

Exclusion criteria: Patients with abnormal uterine anatomy confirmed by hysterosalpingography and hysteroscopy Abnormal karyotype in volunteer couple Positive titer in lupus anticoagulant, antiphospholipid antibody, anticardiolipin antibody, anti beta-2 glycoprotein (anti-B2GPL( antibody Untreated endometriosis Recurrent miscarriage Endometrium less than 7 mm on the day of Human chorionic gonadotropin (hCG) injection Patients with severe male infertility Patients with BMI<30 Untreated hypothyroid patients History of hypersensitivity or anaphylaxis to IVIG History of receiving IVIG (intravenous immunoglobulin) for infertility Under treatment for malignancy History of thromboembolism

Design outcomes

Primary

Measure	Time frame
HCG level. Timepoint: first visit and week 13. Method of measurement: blood test.;Formation of fetal sac. Timepoint: week 13. Method of measurement: Ultrasound sonography.;CD16 level. Timepoint: first visit and week 13. Method of measurement: blood test.;CD56 level. Timepoint: first visit and week 13. Method of measurement: blood test.;Reaching the thirteenth week of pregnancy. Timepoint: 13th week of pregnancy. Method of measurement: Ultrasound sonography.;Abortion. Timepoint: 13th week of pregnancy. Method of measurement: Ultrasound sonography.	—

Measure

Time frame

HCG level. Timepoint: first visit and week 13. Method of measurement: blood test.;Formation of fetal sac. Timepoint: week 13. Method of measurement: Ultrasound sonography.;CD16 level. Timepoint: first visit and week 13. Method of measurement: blood test.;CD56 level. Timepoint: first visit and week 13. Method of measurement: blood test.;Reaching the thirteenth week of pregnancy. Timepoint: 13th week of pregnancy. Method of measurement: Ultrasound sonography.;Abortion. Timepoint: 13th week of pregnancy. Method of measurement: Ultrasound sonography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMitra Sahragard

Iran University of Medical Sciences

Mitra.sahragard@gmail.com+98 21 6435 2528

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026